Literature DB >> 12525660

CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Laurence M Howard1, Katherine L Neville, Lia M Haynes, Mauro C Dal Canto, Stephen D Miller.   

Abstract

Transient CD154 blockade at the onset of Theiler's murine encephalomyelitis virus-induced demyelinating disease ameliorated disease progression for 80 days, reduced immune cell infiltration, and transiently increased viral loads in the central nervous system. Peripheral antiviral and autoimmune T-cell responses were normal, and disease severity returned to control levels by day 120.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12525660      PMCID： PMC140904          DOI： 10.1128/jvi.77.3.2247-2250.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  32 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  High numbers of viral RNA copies in the central nervous system of mice during persistent infection with Theiler's virus.

Authors:  M Trottier; P Kallio; W Wang; H L Lipton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus.

Authors:  J K Olson; A M Girvin; S D Miller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 4.  Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease.

Authors:  J K Olson; J L Croxford; S D Miller
Journal:  Viral Immunol       Date:  2001       Impact factor: 2.257

5.  A virus-induced molecular mimicry model of multiple sclerosis.

Authors:  J K Olson; J L Croxford; M A Calenoff; M C Dal Canto; S D Miller
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

6.  CD40L is critical for protection from demyelinating disease and development of spontaneous remyelination in a mouse model of multiple sclerosis.

Authors:  K M Drescher; L J Zoecklein; K D Pavelko; C Rivera-Quinones; D Hollenbaugh; M Rodriguez
Journal:  Brain Pathol       Date:  2000-01       Impact factor: 6.508

7.  Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice.

Authors:  Y Katz-Levy; K L Neville; A M Girvin; C L Vanderlugt; J G Pope; L J Tan; S D Miller
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Autoimmune intervention by CD154 blockade prevents T cell retention and effector function in the target organ.

Authors:  L M Howard; S D Miller
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

9.  The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system.

Authors:  B Becher; B G Durell; A V Miga; W F Hickey; R J Noelle
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 10.  Pathogenesis of virus-induced immune-mediated demyelination.

Authors:  B S Kim; M A Lyman; B S Kang; H K Kang; H G Lee; M Mohindru; J P Palma
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829
View more
  4 in total

1.  The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys.

Authors:  Simone M Nicholson; Kerry A Casey; Michele Gunsior; Stacey Drabic; William Iverson; Halie Cook; Stephen Scott; Terry O'Day; Subramanya Karanth; Rakesh Dixit; Patricia C Ryan
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

2.  Transition from acute to persistent Theiler's virus infection requires active viral replication that drives proinflammatory cytokine expression and chronic demyelinating disease.

Authors:  Mark Trottier; Brian P Schlitt; Aisha Y Kung; Howard L Lipton
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation.

Authors:  Jared Ehrhart; Demian Obregon; Takashi Mori; Huayan Hou; Nan Sun; Yun Bai; Thomas Klein; Francisco Fernandez; Jun Tan; R Douglas Shytle
Journal:  J Neuroinflammation       Date:  2005-12-12       Impact factor: 8.322

Review 4.  Translational utility of experimental autoimmune encephalomyelitis: recent developments.

Authors:  Andre Ortlieb Guerreiro-Cacais; Hannes Laaksonen; Sevasti Flytzani; Marie N'diaye; Tomas Olsson; Maja Jagodic
Journal:  J Inflamm Res       Date:  2015-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.